Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients
Tóm tắt
Từ khóa
Tài liệu tham khảo
Curtis RE, Boice JD, Moloney WC et al. Leukemia following chemotherapy for breast cancer. Cancer Res 1990; 50: 2741–2746.
Curtis RE, Boice Jr JD, Stovall M et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745–1751.
Fisher B, Rockette H, Fisher ER et al. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience. J Clin Oncol 1985; 12: 1640–1658.
LeBeau MM, Albain KS, Larson RA et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no 5 and 7. J Clin Oncol 1986; 4: 325–345.
Felix CA . Secondary leukemias induced by topoisomerase-targeted drugs. Biochem Biophys Acta 1998; 1400: 233–255.
Kollmannsberger C, Hartmann JT, Kanz L et al. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemo-therapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 1998; 124: 207–214.
Linassier C, Barin C, Calais G et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol 2000; 11: 1289–1294.
Pedersen-Bjergaard J, Andersen MK, Johansson B . Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol 1998; 16: 1897–1898.
Saso R, Kulkarni S, Mitchell P et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 2000; 83: 91–94.
Kumpulainen EJ, Hirvikovski PP, Pukkula E et al. Cancer risk after adjuvant chemo- or chemohormonal therapy for breast cancer. Anticancer Drug 1998; 9: 131–134.
Mellilo LMA, Sajeva MER, Musto P et al. Acute myeloid leukemia following 3M (mitoxantrone, mitomycin, methotrexate) chemotherapy for advanced breast cancer. Leukemia 1997; 1: 2211–2212, (letter).
Mitchell PLR, Treleaven J, Swansbury GJ et al. Secondary acute myeloid leukemia (AML) and myelodysplasia (MDS) following mitoxantrone given as adjuvant therapy for breast cancer. Proc Am Soc Clin Oncol 1996; 15: 127a (abstract 173).
Philpott NJ, Bevan DH, Gordon Smith EC . Secondary leukemia after MMM combined modality therapy for breast carcinoma. Lancet 1993; 341: 1289–1290, (letter).
Cremin P, Flattery M, McCann SR et al. Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Ann Oncol 1996; 7: 745–746.
Chaplain G, Milan C, Sgro C et al. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol 2000; 18: 2836–2842.
Kröger N, Zander AR, Martinelli G et al. Low incidence of secondary myelodysplasia (sMDS) and acute myeloid leukaemia (sAML) after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study of the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2003; 14: 554–558.
Laughlin MJ, McGaughey DS, Crews JR et al. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol 1998; 16: 1008–1012.
Roman-Unfer S, Bitran JD, Hanauer S et al. Acute myeloid leukemia and myelodysplasia following intensive chemotherapy for breast cancer. Bone Marrow Transplant 1995; 16: 163–168.
Martinez-Climent JA, Comes AM, Vizcarra E et al. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. Bone Marrow Transplant 2000; 25: 1203–1208.
Damon LE, Wolf JL, Rugo HS et al. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant 2000; 26: 257–268.
Gisselbrecht C, Extra JM, Lotz JP et al. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Bone Marrow Transplant 1996; 18: 857–863.
Wallerstein Jr R, Spitzer G, Dunphy F et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous bone marrow support for patients with relapsed breast cancer. J Clin Oncol 1990; 8: 1782–1788.
Zander AR, Krüger W, Kröger N et al. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. Bone Marrow Transplant 1996; 18 (Suppl 1): 24–25.
Anderson M, Philip P, Pedersen-Bjergaard J . High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer. Cancer 1990; 65: 460–464.
Bowden GT, Roberts R, Alberts DS et al. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. Cancer Res 1985; 45: 4915–4920.
Carli PM, Sgro C, Parchin-Geneste N et al. Increased therapy-related leukemia secondary to breast cancer. Leukemia 2000; 14: 1014–1017.
Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527–2534.
Stone RM, Neuberg D, Soiffer R et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535–2542.
Milligan DW, Ruiz De Elvira MC, Kolb HJ et al. Secondary leukemia and myelodysplasia after autografting for lymphoma: results from the EBMT. Br J Haematol 1999; 106: 1020–1026.
Nichols G, de Castro K, Wei LX et al. Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. Leukemia 2002; 16: 1673–1679.
Pui CH, Relling MV, Rivera GK et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 1995; 9: 1990–1996.
Kantarjian HM, Keating MJ . Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 1987; 14: 435–438.
Quesnel B, Kantarjian H, Bjergaard J et al. Therapy-related acute myeloid leukemia with t (8;21), inv(16), and t (8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993; 11: 2370–2379.
Hoffmann L, Moller P, Pedersen-Bjergaard J et al. Therapy-related acute promyelocytic leukemia with t (15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and review of the literature. Ann Oncol 1995; 6: 781–788.